CBC Leads Series B for Singapore’s RVAC

Source(s): CBC Group

CBC Group led an undisclosed Series B for RVAC Medicines, a Singapore-based messenger RNA (mRNA) company, with participation from Temasek’s Pavilion Capital, EDBI and GS Holdings. The new round brings the company’s total funding raised to date to USD140m. Read more